<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160815029374N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-11-28</date_registration>
      <primary_sponsor>Mazandaran University of Medical Science.</primary_sponsor>
      <public_title>ٍEffects of myo-inositol on induction of ovulation</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the effects of  myo-inositol plus clomiphene citrate with metformin plus clomiphene citrate on induction of ovulation among patients with polycystic ovarian syndrome.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-12-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>164</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/31123</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is done based on the Rearrangement of four blocks before the  initiation of treatment cycle by one nurse. In fact, only the nurse knows which patient is under the metformin or myo-inositol treatment, or not. Physicians do not know which patient is undergoing intervention, but patients know about the intervention due to informed consent,therefore, it is not possible to concealed the patients in this group, Blinding description: Reduction of Bias
Enhancing Scientific Validity
Adherence to Ethical Principles
Compliance with International Standards.</study_design>
      <phase>3</phase>
      <hc_freetext>Diseases of the genitourinary system.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Use of Inofolic powedr (including myo-inositol 2 gr plus folic acid tab 200 microgram, Shafayab Co from Lolipharma Co), 25 mg twice  daily till 12 weeks. Intervention 2: Control group: Use of metrformin tablet (Gly-once, 500 mg, Coshan farmed Co), three times a day till 12 weeks. Intervention 3: Intervention group: Use of Clomiphene citrate tablet (Clomid, 50 mg, Iran Hormone Co), 100 mg daily from 5 till 9 of menstruation.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Marzieh Zamaniyan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>233 plaque, Ground Floor, IVF ward, Imam Khomeini Hospital, Amir Mazandarani Ave, Sari.</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>139944176</zip>
        <telephone>+98 11 3336 5724</telephone>
        <email>m.zamanian@mazums.ac.ir</email>
        <affiliation>Infertility Center, Department of Obstetrics and Gynecology, Mazandaran University of Medical Scienc</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Marzieh Zamaniyan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>233 plaque, Ground Floor, IVF ward, Imam Khomeini Hospital, Amir Mazandarani Ave, Sari.</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>13934313</zip>
        <telephone>+98 11 3336 5724</telephone>
        <email>marziehzamaniyan@gmai.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women aged 20-35 year
Suffering from polycystic ovary syndrome
Anovulation and infertility for one year or more</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Other condition with hyperandrogenism and anovulation (adrenal, hypophysis or ovarian disorders)
Other causes of infertility (male factor or tubal factor)
Use of hormones or drugs that affect ovulation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97; N98</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female infertility; Complications associated with artificial fertilization</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Use of Inofolic powedr (including myo-inositol 2 gr plus folic acid tab 200 microgram, Shafayab Co from Lolipharma Co), 25 mg twice  daily till 12 weeks.</i_keyword>
      <i_keyword>Control group: Use of metrformin tablet (Gly-once, 500 mg, Coshan farmed Co), three times a day till 12 weeks.</i_keyword>
      <i_keyword>Intervention group: Use of Clomiphene citrate tablet (Clomid, 50 mg, Iran Hormone Co), 100 mg daily from 5 till 9 of menstruation.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ovulation rate. Timepoint: On day 12 and 14 and 20 of cycle. Method of measurement: Questionnare.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Clinical pregnancy rate. Timepoint: Forth weeks after positive pregnancy test. Method of measurement: Questionnare.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Science.</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-06-27</approval_date>
        <contact_name>Ethics committee of Mazandaran University of Medical Science.</contact_name>
        <contact_address>240 Plaque, Third floor, Mazandaran University of Medical Sciences, Joybar street, Sari, Iran Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
